Covid-19 Vaccine Maker Blames Problems on Producing Two Different Shots
May 19 2021 - 10:50AM
Dow Jones News
By Peter Loftus
Emergent BioSolutions Inc. blamed some of the problems at its
Baltimore drug plant on having to produce two Covid-19 vaccines at
large scale, which the company said strained the capacity of its
equipment.
Emergent, a contract drug manufacturer, described some of the
problems and its plan to fix them in a letter to the U.S. Food and
Drug Administration, responding to the agency's finding of various
deficiencies during an April inspection.
A subcommittee of the U.S. House Committee on Oversight and
Reform released the April 30 letter on Wednesday, ahead of a
hearing by the panel about Emergent.
Emergent was producing a bulk key vaccine ingredient for Johnson
& Johnson's Covid-19 vaccine, but a mishap led to the
contamination of material that could have yielded up to 15 million
doses during January and February.
The contamination came from viral material similar to what was
used in the production of AstraZeneca PLC's Covid-19 vaccine at the
same plant, according to a memo from the Democratic staff of the
House committee to members.
The incident ruined the batch of J&J's vaccine ingredient
and led to a halt in production of the J&J vaccine, as well as
a decision to relocate production of AstraZeneca's vaccine
elsewhere. In addition, J&J took over manufacturing at the
Emergent plant.
The FDA's inspection of the Emergent plant found it didn't
maintain clean, sanitary conditions and didn't take proper steps to
prevent contamination. The inspection found the building and
equipment, including refrigerators, weren't big enough to support
large-scale manufacturing in a way that would ensure clean
conditions.
Emergent, in its April 30 response, said: "The sudden scale-up
to full-scale manufacturing activities for two different Covid-19
vaccine drug substances strained the capacity of Emergent's"
refrigerators.
The company said it has cleaned and organized them and will
purchase additional refrigerators.
The company also said its plant "experienced a dramatic increase
in storage and staging demands as the facility operated at full
capacity for the first time." The company said it has changed
procedures to mitigate the risk of contamination.
Emergent, based in Gaithersburg, Md., said in a statement
Wednesday that its role in responding to the Covid-19 pandemic is
"unlike any we have confronted before." The company said it is
focused on releasing a vaccine ingredient that is currently under
evaluation and on resuming vaccine production.
The House committee also released documents showing that
Emergent has charged the federal government $27 million a month in
reservation fees to be ready to manufacture vaccines.
The government has paid Emergent $271 million of these fees to
date, but has partially stopped payment since learning of the
contamination, the committee's Democratic staff said in the memo to
members.
Emergent Chief Executive Robert Kramer and Executive Chairman
Fuad El-Hibri are slated to testify at the hearing, which is
scheduled to start at 10:30 a.m. ET.
(END) Dow Jones Newswires
May 19, 2021 10:35 ET (14:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Apr 2023 to Apr 2024